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Seth M. Pollack,1,2 Seth M. Steinberg,3 Jeanne Odom,2 Robert M. Dean,2,4 Daniel H. Fowler,2
Michael R. Bishop2The hematopoietic cell transplantation comorbidity index (HCT-CI), a weighted index of 17 pretransplanta-
tion comorbidities, has been validated in nonmyeloablative and myeloablative allogeneic hematopoietic stem
cell transplantation (HSCT) studies, but it has not been specifically tested in patients with non-Hodgkin lym-
phoma (NHL) receiving reduced-intensity conditioning (RIC). We performed a retrospective analysis to as-
sess the impact of the HCT-CI on outcomes of NHL patients treated with HSCT relative to treatment-
related mortality (TRM), disease-related mortality (DRM), with a specific emphasis on overall survival
(OS). Individual pretransplantation and disease-related factors also were analyzed with HCT-CI relative to
their impact on OS. All patients were uniformly treated with an identical pretransplantation induction reg-
imen and an identical RIC regimen (cyclophosphamide [Cy]/fludarabine [Flu]), and received T cell–replete
allografts from HLA-matched siblings. The analysis included 63 NHL patients with a median HCT-CI score
of 2 (range, 0 to 11). The HCT-CI (0 to 2 comorbidities vs 31 comorbidities) demonstrated a potential as-
sociation with TRM, but not with DRM, at 100 days (4.5% vs 26.3%) and at 1 year (13.6% vs 36.8%) posttrans-
plantation. The factor most strongly associated with OS was response to pretransplantation chemotherapy
(P 5 .0001), based on a composite measure. In a Cox model, pretransplantation chemotherapy response
remained the most important factor (P\.0001) relative to OS, and there was a trend (P 5 .056) toward
HCT-CI adding predictive value for OS. Although HCT-CI may be useful for predicting TRM, our data further
underscore the importance of response to chemotherapy before transplantation as a predictor of overall
transplantation outcome in NHL patients being considered for RIC allogeneic HSCT.
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6/j.bbmt.2008.11.023non-Hodgkin lymphoma (NHL) [1,2]. Previously,
the option of allogeneicHSCTwas relatively contrain-
dicated for patients with NHL who were older, had
comorbidities, or had previously received high-dose
therapy and autologous HSCT [3]. The introduction
of nonmyeloablative and reduced-intensity condition-
ing (RIC) regimens, which are associated with de-
creased acute morbidity and mortality, made the
option of allogeneic HSCT available to many of these
patients [4-7]. It has been demonstrated that nonmye-
loablative and reduced-intensity allogeneic HSCT can
result in sustained remission in patients with refractory
and relapsed NHL [7,8]. These transplantations have
been performed successfully in older patients, patients
who had undergone previous autologous stem cell
transplantations, and patients with preexisting comor-
bidities [6,9].
Despite evidence that nonmyeloablative and
reduced-intensity allogeneic HSCT may be successful223
224 Biol Blood Marrow Transplant 15:223-230, 2009S. M. Pollack et al.in patients with advanced NHL, determining whether
or not certain patients are good candidates for trans-
plantation can be difficult. Multiple patient-related
factors, including age and performance status, are as-
sociated with transplantation outcomes [10,11]. In
addition, disease-related factors (particularly chemo-
therapy sensitivity before transplantation) have been
identified as prognostic factors for overall transplanta-
tion success in the nonmyeloablative and RIC settings
[8,9,12]. The assessment of whether nonmyeloablative
or RIC allogeneic HSCT is an appropriate option for
patients with an NHL is even more difficult, because
many of these patients have multiple adverse patient-
and disease-related factors, as well as coexisting co-
morbidities. Because each of these factors has a unique
impact on transplantation outcome, the ability to
quantify the collective impact of these factors would
be useful in better determining the applicability of
nonmyeloablative or reduced-intensity allogeneic
HSCT to this heterogeneous patient population.
Various comorbidity indices, including the Charl-
son comorbidity index and the Kaplan-Feinstein scale,
have been developed in attempts to facilitate pretrans-
plantation patient counseling and aid researchers com-
paring varied patient populations [13,14]. These
assessment tools, particularly the Charlson comorbid-
ity index, have been successful in predicting mortality
risk in several medical conditions, including allogeneic
HSCT. But these tools did not include several ther-
apy- and disease-related factors that have been demon-
strated to affect outcomes related to allogeneicHSCT.
To address these inadequacies, a new assessment tool
specific to HSCT was developed by investigators
from the Fred Hutchinson Cancer Research Center
[15]. This assessment tool, the hematopoietic cell trans-
plantation comorbidity index (HCT-CI), is a weighted
index calculated from 17 comorbidities and based on
data from more than 1000 diverse patients who under-
wentHSCT.TheHCT-CI has demonstrated its supe-
riority in predicting outcomes in HSCT patients
compared with the Charlson comorbidity index.
The HCT-CI has been extensively evaluated in
patients receiving myeloablative and nonmyeloabla-
tive conditioning regimens [16,17], but it has not
been specifically tested in a cohort of NHL patients
receiving an RIC regimen before allogeneic HSCT.
Because of the relative heterogeneity in the degree of
myelosuppression, immunosuppression, and clinical
outcomes with various nonmyeloablative and RIC reg-
imens, exploring the utility of the HCT-CI with dif-
ferent regimens is of interest. Using a cohort of
NHL patients who had been uniformly treated with
RIC allogeneic HSCT, we performed a retrospective
analysis comparing the HCT-CI with individual
comorbidities and disease-related factors relative to
their impact on transplantation outcomes, with a spe-
cific emphasis on overall survival (OS).METHODS
Patient Selection
Patients with NHL who were enrolled in the
sequential National Cancer Institute protocols 99-C-
0143, 03-C-0077, and 04-C-0055, from January 2000
through November 2005, were included in this retro-
spective analysis. All 3 protocols required that the
patient had disease with less than a complete response
to primary treatment, relapsed and failed to respond to
second-line therapies, or relapsed or progressed after
autologous HSCT. A patient was not required to
have chemotherapy-sensitive disease to participate in
any of these protocols. All protocols had nearly identi-
cal eligibility criteria, which included an Eastern
Cooperative Oncology Group (EGOG) performance
status assessment of 0 to 2 (Karnofsky performance sta-
tus . 60%), aged . 18 years, and consenting first-de-
gree relative matched at HLA-A, -B, and -DR.
Although severe cardiac, pulmonary, renal, or hepatic
dysfunction was reason for exclusion from the study,
mild to moderate organ dysfunction was permitted,
including (1) cardiac left ventricular ejection fraction
(LVEF) as low as 45%, (2) pulmonary diffusion capac-
ity for carbon monoxide (DLCO) as low as 50% of the
expected value when corrected for hemoglobin, (3) se-
rum creatinine level up to 1.5 mg/dL and creatinine
clearance as low as 50 mL/min/1.73 m2, and (4) serum
total bilirubin as high as 2.5 mg/dL and serum alanine
aminotransferase and aspartate aminotransferase
values as high as 2.5 times the upper limit of normal.
TheNationalCancer Institute’s PathologyLaboratory
confirmed each patient’s diagnosis using the World
Health Organization (WHO) classification system.
The protocols in which the patients participated were
approved by the National Cancer Institute Institu-
tional Review Board, and informed written consent
was obtained from each patient and his or her donor.
All patients were treated in a uniform manner. On
enrollment onto their respective protocols, all patients
received an induction chemotherapy regimen,
EPOCH-F (consisting of etoposide, prednisone, vin-
cristine, cyclophosphamide [Cy], doxorubicin, and flu-
darabine [Flu]), administered at conventional doses
[10]. Patients with lymphoma expressing CD20 also
received rituximab with the induction chemotherapy.
The purpose of the induction chemotherapy was to
further assess chemotherapy sensitivity, reduce circu-
lating host T cells, and provide tumor control before
proceeding to transplantation. All patients then
received an identical reduced-intensity conditioning
regimen consisting of Cy (4.8 g/m2) and Flu (120 mg/
m2), both administered over 4 days, followed by a T
cell–replete peripheral blood allograft collected
from an HLA-matched siblings after mobilization
with filgrastim. All patients received a cyclosporine
Biol Blood Marrow Transplant 15:223-230, 2009 225HCT-CI in NHL Patients Receiving Allogeneic Stem Cell Transplantation(CsA)-based graft-versus-host disease (GVHD) pro-
phylaxis regimen. The 3 protocols differed by the
addition of donor T helper cells with type 2 cytokine
profile (Th2) cells, methotrexate (MTX), and/or siro-
limus for prevention of GVHD [18].Variables
The following variables were analyzed for their po-
tential association with OS: HCT-CI score, ECOG
performance status, LVEF, DLCO, creatinine, creati-
nine clearance, total bilirubin, body mass index (BMI),
CD341 cell dose within the allograft, age, number of
previous regimens (including the pretransplantation
induction chemotherapy regimen), response to induc-
tion chemotherapy, cytomegalovirus (CMV) status,
sex, history of previous autologous transplantation,
GVHD prophylaxis, and histology. HCT-CI scores
(0 to 2 vs 31) were calculated using the method de-
scribed by Sorror et al. [15], based on comorbidities
present at study enrollment.
The following definitions were used for response
to induction chemotherapy during the trial. Complete
response (CR) was defined according to standard crite-
ria available at the time the studies were performed, as
regression of all lymph nodes to normal size (# 1.5
cm), resolution of soft tissue masses or palpable orga-
nomegaly resulting from lymphoma, and clearance of
bone marrow infiltration if present previously [19].
As with standard criteria, partial response (PR) re-
quired a minimum 50% reduction in the sum of the
products of the diameter of reference lesions without
enlargement of other lesions, including liver and/or
spleen. Progressive disease (PD) was defined by con-
ventional criteria (appearance of any new lesion or
a minimum 50% increase in sum of the products of
the diameter of an existing lesion). Patients who did
not meet criteria for PD, PR, or CR based on these
definitions were categorized as having stable disease
(SD). In addition, response to the composite response
to pretransplantation chemotherapy (response to pre-
enrollment chemotherapy 1 response to induction
chemotherapy) was studied as CR 1 PR versus PD
1 SD as well as CR 1 PR 1 SD PD.
For histological analysis, patients were classified as
diffuse large B cell lymphoma, follicular lymphoma
(the 2 most common histologies in this analysis), or
‘‘other’’ (those without specific histological features of
diffuse large B cell or follicular lymphoma, or with
disease that transformed from one histological subtype
to another). Because of the large number and heteroge-
neity of patients falling in the ‘‘other’’ category, disease
was also classified and analyzed as either ‘‘indolent’’ or
‘‘aggressive,’’ as defined by the Physician Data Query
Modification of the Revised European American
Lymphoma (PDQ-REAL) classification of lympho-
proliferative diseases (see http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-Hodgkins/Health
Professional/page3#Section_31). Treatment-related
mortality (TRM) and disease-related mortality
(DRM) were calculated from date of transplantation
to date of death or to date of last follow-up.
Statistical Analysis
Survival was calculated from the date of stem cell
infusion until date of death or last follow-up. Explor-
atory univariate analyses for survival were performed
using Kaplan-Meier curves to report the probability
of survival as a function of time. The significance of
the difference between curves was determined using
the log-rank test with 2-tailed P values. Because fur-
ther evaluation of certain variables required dividing
continuous parameters into quartiles and then using
these preliminary results to determine where to choose
the best of the 3 places to divide the patients for a more
definitive evaluation, adjusted P values equal to triple
the unadjusted value, along with the unadjusted value,
are reported for those variables.
Individual prognostic factors with unadjusted
P values\ .10 were included for evaluation in an initial
Cox model. A backward selection algorithm was used
to select the final model. To test the gain to the model
by including the HCT-CI, this variable was not in-
cluded in the initial model; once the model was
selected based on the more standard parameters, the
HCT-CI was added to determine whether this param-
eter provided additional, statistically significant im-
provement to the model.
The HCT-CI also was analyzed using cumulative
incidence curves of TRM,withDRMas the competing
outcome, following the method described by Gooley
et al. [20]. Likewise, curves for DRM were created
using TRM as the competing outcome.RESULTS
Patients
Table 1 summarizes characteristics of the 63 pa-
tients with NHL included in the analysis. The median
patient age was 53 years, and the median ECOG per-
formance status score was 1. The 2 most common his-
tologies were diffuse large B cell lymphoma (n 5 20)
and follicular lymphomas (n 5 12). The remaining
histologies were quite diverse, including chronic lym-
phocytic leukemia, mantle cell lymphoma, marginal
zone lymphoma, and T cell lymphomas, among
others. Based on the PDQ-REAL classification
system, 77% of patients were classified as having an
‘‘aggressive’’ histology . The median BMI was 25.2;
only 4 patients had a BMI . 35. The median HCT-
CI score was 2 (range, 0 to 11). Forty-four patients
had a HCT-CI score of 0 to 2, and 19 patients had
a score of 3 or greater.
Table 1. Patient Characteristics
Pretransplantation and disease-related factors
Total number of patients 63
Median age, years 53 (range, 32 to 74)
Serum creatinine, median, mg/dL 0.8 (range, 0.5 to 1.7)
DLCO, median % predicted 89.75% (range, 57.0%
to 125.0%)
LVEF 58% (range, 34% to 72%)
Sex, n (%)
Donor
Male 33 (52%)
Female 30 (48%)
Recipient
Male 37 (59%)
Female 26 (41%)
CMV serology, n (%)
Donor
Positive 35 (56%)
Negative 27 (44%)
Recipient
Positive 39 (63%)
Negative 23 (37%)
Previous chemotherapy regimens,
median, n
4 (range, 1 to 9)
Previous autologous HSCT, n (%)
Yes 14 (22%)
No 49 (78%)
NHL histology, n (%)
Diffuse large B cell lymphoma 20 (32%)
Follicular lymphoma 12 (19%)
T cell lymphomas 11 (17%)
Mantle cell lymphoma 7 (11%)
Transformed B cell lymphomas 7 (11%)
Chronic lymphocytic leukemia/small
lymphocytic lymphoma
4 (6%)
Marginal zone 2 (3%)
PDQ-REAL disease classification, n (%)
Indolent 14 (22%)
Aggressive 49 (78%)
Response to last therapy before study
enrollment, n (%)
Chemotherapy-sensitive 23 (37%)
Chemotherapy-resistant 33 (52%)
Untested 7 (11%)
Response to pretransplantation
induction chemotherapy, n (%)
Complete response 7 (11%)
Partial response 17 (27%)
Stable disease 26 (41%)
Progressive disease 10 (16%)
Nonevaluable 3 (5%)
Median ECOG performance status 1 (range, 0 to 2)
Median CD34+ dose,  106 cells/kg 7.3 (range, 3.46 to 17.8)
HCT-CI
Median HCT-CI score 2 (range, 0 to 11)
Distribution of HCT-CI scores, n (%)
0 to 1 30 (48%)
2 14 (22%)
3 7 (11%)
$ 4 12 (19%)
Individual comorbidities as defined
by the HCT-CI, n (%)
Arrhythmia 1 (2%)
Cardiac 7 (11%)
Inflammatory bowel disease 0 (0)
Diabetes 1 (2%)
Cerebrovascular disease 0 (0)
Psychiatric 6 (9%)
Mild hepatic 16 (25%)
Obesity 5 (8%)
Infection 19 (30%)
Rheumatologic 1 (2%)
Peptic ulcer disease 1 (2%)
Moderate/severe renal 0 (0)
Moderate pulmonary 14 (22%)
(Continued)
Table 1.
Previous solid tumor 1 (2%)
Heart valve disease 1 (2%)
Severe pulmonary 7 (11%)
Moderate/severe hepatic 2 (3%)
DLCO indicates pulmonary diffusion capacity for carbon monoxide;
LVEF, left ventricular ejection fraction; CMV, cytomegalovirus; HSCT,
hematopoietic stem cell transplantation; NHL, non-Hodgkin lymphoma;
PDQ-REAL, Physician Data Query Modification of the Revised Euro-
pean American Lymphoma classification of lymphoproliferative diseases;
HCT-CI, hematopoietic cell transplantation comorbidity index.
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imens before transplantation. Although all patients
had relapsed or refractory disease at the time of study
enrollment, 37% of evaluable patients were found to
have chemotherapy-sensitive disease to salvage ther-
apy before study enrollment. Seven patients had un-
treated relapse at time of study enrollment. Response
to induction chemotherapy correlated well with pre-
enrollment treatment response; 96% of patients were
found to have maintained or improved on their previ-
ous response after treatment with EPOCH-F. Among
patients with chemotherapy-resistant disease at enroll-
ment, 27% actually had a response to EPOCH-F, and
an additional 45% had SD. The overall composite
response to pretransplantation chemotherapy was as
follows: CR, 13%; PR, 43%; SD, 17%; and PD, 27%.Transplantation Outcomes
TRM and DRM
For patients who were alive as of the date of anal-
ysis, the median time from transplantation to last fol-
low-up was 35.5 months (range, 6 to 80.6 months).
After transplantation, 16 patients died from treat-
ment-related causes and 14 died from disease-related
causes. The cumulative incidence of TRM, adjusting
for the impact of the competing factor of death from
progression, was 11.1% at 100 days posttransplanta-
tion and 20.7% at 12 months posttransplantation
(Figure 1A). The cumulative incidence of DRM,
adjusting for the impact of the competing effect of
TRM, was 3.2% at 100 days posttransplantation and
16.2% at 12 months posttransplantation (Figure 1A).
The cumulative incidence curves for TRM and
DRM based on HCT-CI score are summarized in
Table 2 and depicted in Figure 2. The HCT-CI (0
to 2 comorbidities vs 31 comorbidities) demonstrated
a potential association with TRM at 100 days (4.5% vs
26.3%) and 1 year (13.6% vs 36.8%) posttransplanta-
tion. The HCT-CI (0 to 2 vs 31) was not statistically
associated with DRM at 100 days (4.5% vs 0) or 1 year
(18.3% vs 11.7%) posttransplantation.
OS
Themedian OS for all 63 patients was 24.1 months
(Figure 1B). The 12- and 24-month probabilities of
Figure 1. Transplantation outcomes in patients (n 5 63) undergoing
reduced-intensity allogeneic HSCT. (A) Cumulative incidences of TRM
and DRM. (B) Probability of OS.
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probability of death from all causes at 100 days was es-
timated to be 9.1% for patients with HCT-CI scores
of 0 to 2 and 26.3% for those with scores of 31. Mor-
tality from all causes at 1 year was estimated to be 32%
for patients with anHCT-CI score of 0 to 2 and 48.5%
for those with a score of 31 (Figure 2C).
Univariate Analysis and Resulting Cox Model for
OS
In univariate analysis, various factors were identi-
fied as having a potential association with OS, with un-
adjusted P values \ .10 (Table 3), and thus were
selected for inclusion in an initial Cox model. AfterTable 2. Estimated Probabilities of Mortality Based on HCT-
CI Score
100 Days 1 Year
0 to 2 $ 3 0 to 2 $ 3
All causes of mortality 9.1% 26.3% 32% 48.5%
Cumulative incidence of TRM 4.5% 26.3% 13.6% 36.8%
Cumulative incidence of DRM 4.5% 0 18.3% 11.7%
HCT-CI indicates hematopoietic cell transplantation comorbidity index;
TRM, treatment-related mortality; DRM, disease-related mortality.a backward elimination of variables, the composite
pretransplantation response (either PD vs SD 1 PR
1 CR or PD 1 SD vs PR 1 CR) along with GVHD
prophylaxis (CsA 1 Th2 vs all other forms), CMV
donor status and creatinine clearance were found to be
jointly statistically significant for an association with
survival; response to EPOCH-F (SD 1 PR 1 CR vs
PD) also was important in some models (Table 4A).
The HCT-CI parameter (0-2 vs 31) was marginally
statistically significant when adjusted for the parame-
ters included in the first model presented in the bottom
part of Table 4 (P5 .056). This parameter did not re-
tain its level of significance in a related model includ-
ing both the pretransplantation response and
EPOCH-F response (P 5 .14; data not shown).DISCUSSION
As the use of nonmyeloablative and RIC regimens
opens up the option of allogeneic HSCT to patients
with multiple comorbidities, it can be difficult to de-
termine when risks outweigh the benefits of this poten-
tially life-prolonging therapy. Our data demonstrate
the potential validity of the HCT-CI as an instrument
for estimating survival in a group of patients with re-
lapsed and refractory NHL undergoing RIC alloge-
neic HSCT from HLA-matched siblings. HCT-CI
scores of 31 were statistically associated with de-
creased OS in univariate analysis, and there was a trend
toward decreased OS in multivariate analysis. Also,
specific individual transplant and tumor characteristics
were predictive of OS, particularly response to pre-
transplantation chemotherapy. Interestingly, NHL
histology, as defined by the PDQ-REAL classification
system, did not affect survival after allogeneic HSCT;
this result differs from those obtained in previous stud-
ies [21,22].
The fact that in the Cox model analysis, the HCT-
CI exhibited a trend toward a statistically significant
association with overall transplantation outcome high-
lights the importance of disease-related factors in
NHL patients being considered for RIC allogeneic
HSCT. Chemotherapy resistance has been identified
as important prognostic factor in previous analyses of
both nonmyeloablative and RIC studies in NHL pa-
tients, and chemotherapy-sensitive disease is an eligi-
bility requirement in many trials, including those
being conducted by the Blood andMarrowTransplant
Clinical Trials Network in the United States [4,6,8,9].
Our analysis, which did not exclude patients with ei-
ther SD or PD before transplantation, supports and
further explicates these results based on specific re-
sponses to pretransplantation chemotherapy. Some-
thing that remains unclear from our analysis is
whether the chemotherapy sensitivity of the disease
or the disease remission status before transplantation
Figure 2. Impact of HCT-CI on transplantation outcome: (A) TRM; (B)
DRM; (C) OS.
Table 3. Variables Considered for Potential Incorporation
into an Initial Cox Model of Survival
Variable
P value (unadjusted;
adjusted if appropriate)
HCT-CI .026; .052*
ECOG performance status (0 vs $ 1) .094
LVEF (< 63% vs $ 63%) .035; .11
DLCO (# 100 vs $ 100.1) .013; .038
Creatinine (< 0.8 vs $ 0.9 mg/dL) .075; .23
Creatinine clearance (< 87 vs $ 87 mL/min) .036; .23
Total bilirubin (< 0.7 vs $ 0.7) .046; .14
BMI †
Previous regimens (< 5 vs $ 5) .045; .13
EPOCH-F response (PR, CR, and PD vs SD) .0025
CD34+ cell dose †
Donor CMV (positive vs negative) .094
Recipient CMV (positive vs negative) .33
Donor or recipient CMV positive (yes vs no) .61
Donor (male vs female) .45
Recipient (male vs female) .72
Sex (match vs mismatch) .28
Age, years (30 to 50 vs $ 51) .11; .33
Histology (indolent vs aggressive)‡ .32
Previous autologous HSCT (yes vs no) .96
GVHD prophylaxis
CsA alone versus CsA + Th2 .25
CsA alone versus CsA + MTX .61
CsA alone versus CsA + rapamicin
(alone or with Th2)
.29.
CsA + Th2 versus CsA + MTX .033
CsA + Th2 versus CsA + rapamicin
(alone or with Th2)
.077
CsA + MTX versus CsA+ rapamicin
(alone or with Th2)
.61
CsA + Th2 versus all others .018; .054
HCT-CI indicates hematopoietic cell transplantation comorbidity index;
DLCO, pulmonary diffusion capacity for carbonmonoxide; PR, partial
response; CR, complete response; PD, progressive disease; SD, stable
disease; CMV, cytomegalovirus; CsA, cyclosporine A; MTX, methotrexate.
*Adjusted P value is double the unadjusted value, because there were 2
possible groupings. Variables with unadjusted P values < .10 were incor-
porated into a Cox model of survival.
†Inconsistent ordering in association of categories for this parameter
relative to response; thus, the parameter would not be included in
a Cox model.
‡Based on the PDQ-REAL classification of lymphoproliferative diseases.
228 Biol Blood Marrow Transplant 15:223-230, 2009S. M. Pollack et al.is of greater clinical importance—both of these factors
have been previously observed to potentially influence
posttransplantation outcomes [23,24]. This analysis
could be interpreted as suggesting that patients who
have achieved a clinically significant remission, and
thus have a lower disease burden, are more likely to
have a successful outcome after transplantation. This
would be consistent with the theory that low volumes
of malignant disease are most vulnerable to the graft-
versus-malignancy effect [25]. The other possibilities
are that resistance to chemotherapy is associated with
a lack of response to cellular therapy (ie, the ‘‘graft-
versus-lymphoma effect’’), or that response to the
effects of cytotoxic chemotherapy is essential for suc-
cessful outcomes with allogeneic HSCT [26]. Alterna-tively, or in addition, it is possible that patients with
chemotherapy-resistant NHL fare more poorly after
transplantation because of in part the toxicity from
posttransplantation interventions that are necessitated
by the progression of malignancy, including early dis-
continuation of GVHD chemoprophylaxis, adminis-
tration of donor lymphocyte infusions, and
administration of chemotherapy posttransplantation.
In light of this information, it is possible that the
option of allogeneic HSCT may be optimally per-
formed relatively early in the disease course before
exposure to regimens that may potentially generate
chemotherapy resistance and/or result in excessive tox-
icity. Patients with good responses to previous chemo-
therapy who have an HCT-CI score \ 3 are most
likely to do well after RIC allogeneic HSCT. Our
results indicate that patients with very poor response
Table 4. Cox Model Results Based on the Backward Selection Model, with and without Adding in the Effect of HCT-CI
Variable Parameter Estimate P Value
Hazard Ratio (95%
Confidence Interval)
Without adding in the effect of HCT-CI
Pretransplantation composite response (CR + PR + SD vs PD) 2.411 < .0001 11.147 (4.660 to 26.662)
GVHD prophylaxis (CsA + Th2 vs other) 21.836 < .0001 0.159 (0.064 to 0.396)
CMV donor (positive vs negative) 21.479 .0007 0.228 (0.096 to 0.538)
Creatinine clearance (< 87 vs $ 87 mL/min) 21.441 .0013 0.228 (0.098 to 0.570)
Adding in the effect of HCT-CI
HCT-CI (0 to 2 vs 3+) 0.773 .056 2.166 (0.981 to 4.784)
Pretransplantation composite response (CR + PR + SD vs PD) 2.396 <.0001 10.983 (4.472 to 26.976)
GVHD prophylaxis (CsA + Th2 vs other) 22.003 <.0001 0.135 (0.053 to 0.344)
CMV donor (positive vs negative) 21.527 0.0005 0.217 (0.092 to 0.515)
Creatinine clearance (< 87 vs $ 87 mL/min) 21.558 0.0007 0.211 (0.086 to 0.518)
HCT-CI indicates hematopoietic cell transplantation comorbidity index; CR, complete response; PR, partial response, SD, stable disease; PD, progressive
disease; CsA, cyclosporine A; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
Biol Blood Marrow Transplant 15:223-230, 2009 229HCT-CI in NHL Patients Receiving Allogeneic Stem Cell Transplantation(ie, progressive disease) to chemotherapy are unlikely
to benefit from RIC allogeneic HSCT, but patients
with stable disease appear to derive potential benefits.
If such patients are considered for transplantation,
they are most likely to do well if they have a low
HCT-CI score (\ 3). Patients who have had poor re-
sponse to chemotherapy and also have multiple co-
morbidities, as reflected in high HCT-CI scores
(31), are unlikely to do well after transplantation.
This group of patients has increased incidences of re-
lapse, death related to relapse, and nonrelapse mortal-
ity (NRM); they should be considered for therapeutic
options other than RIC allogeneic HSCT. Unfortu-
nately, for this group, nontransplantation options
also have a relatively limited success rate. Our analysis
confirms that the HCT-CI may be of potential clinical
utility in patients with NHL undergoing RIC alloge-
neic HSCT. However, in light of the retrospective na-
ture of the analysis, which was limited to patients with
NHL undergoing RIC allogeneicHSCT, there results
need to be verified in larger patient groups. If our find-
ings are substantiated, we would expect them to be use-
ful to physicians in attempting to evaluate whether
patients are appropriate candidates for this procedure
as well as in patient counseling regarding the potential
risks and benefits of the procedure.ACKNOWLEDGMENTS
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